Dr George D. Yancopoulos, Regeneron’s chief scientific officer, said: “We are honoured that the Galien Foundation has recognised Inmazeb […] Our ability to rapidly respond to Ebola was based ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Who Are The Key Players In The Inmazeb Market? Major players shaping the Inmazeb market include Regeneron Pharmaceuticals Inc. Industry transformations, innovative research and advancement in ...

NEW YORK, Jan 13 (Reuters) - Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals (REGN.O), opens new tab, Illumina (ILMN.O), opens new ...